Fusion Antibodies plc (AIM:FAB)
London · Delayed Price · Currency is GBP · Price in GBX 10.22
-0.53 (-4.92%)
Jul 24, 2026, 4:09 PM GMT
Fusion Antibodies Revenue
Fusion Antibodies had revenue of 838.00K GBP in the half year ending September 30, 2025, with 54.90% growth. This brings the company's revenue in the last twelve months to 1.60M, down -11.43% year-over-year. In the fiscal year ending March 31, 2025, Fusion Antibodies had annual revenue of 1.97M with 72.98% growth.
Revenue (ttm)
1.60M
Revenue Growth
-11.43%
P/S Ratio
8.42
Revenue / Employee
66.50K
Employees
24
Market Cap
13.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.97M | 829.00K | 72.98% |
| Mar 31, 2024 | 1.14M | -1.77M | -60.84% |
| Mar 31, 2023 | 2.90M | -1.90M | -39.55% |
| Mar 31, 2022 | 4.80M | 634.00K | 15.22% |
| Mar 31, 2021 | 4.17M | 270.00K | 6.93% |
| Mar 31, 2020 | 3.90M | 1.71M | 78.51% |
| Mar 31, 2019 | 2.18M | -508.74K | -18.91% |
| Mar 31, 2018 | 2.69M | 776.79K | 40.59% |
| Mar 31, 2017 | 1.91M | 432.69K | 29.21% |
| Mar 31, 2016 | 1.48M | 571.97K | 62.90% |
| Mar 31, 2015 | 909.29K | 186.25K | 25.76% |
| Mar 31, 2014 | 723.05K | 318.05K | 78.53% |
| Mar 31, 2013 | 405.00K | -87.30K | -17.73% |
| Mar 31, 2011 | 492.29K | 55.35K | 12.67% |
| Mar 31, 2010 | 436.95K | -24.11K | -5.23% |
| Mar 31, 2009 | 461.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 9.76M |
| IXICO | 7.28M |
| SkinBioTherapeutics | 5.23M |
| Arecor Therapeutics | 1.71M |
| Aptamer Group | 1.38M |
| OptiBiotix Health | 1.17M |
| Genflow Biosciences | 585.61K |
| Thalia Therapeutics | 7.26K |